InSite Vision Global Online Auction
Featured Assets
- ST Charles 6' Fume hood Model:FH-170 with Tel digital air flow monitor Model: AFA1000
- Buchi Rotavapor Condenser and Water Bath System
- FTS Cleanroom Freeze Dryer System
- American Air Filter Cleanroom fume Hood 58" X 40" X 8'
- Forma Scientific Fume Hood Model: 1102
- Pentronic Gentinge Autoclave Sterilizer Model: GE 669 ARB-2 High Vacuum steam sterilizer
- Atlas Suntest Irradiance Tester Model: Sunset CPS+
- Shimanzu Total Organic Carbon Analyzer model: TOC-V CSH and Shimadzu Autosampler: ASI-V
- Brookfield Digital Viscometer Model: LVTDV-II
- Biomerieux Vitek 2 Compact 30 Biomerieux Vitek 2 Compact Fully Automated ID/AST Instrument Microbial Analyzer
- Met One Digital Laser Particle Counter model: A2400
- Amsco Eagle Series Vacamatic Sanitizer Autoclave
- Kewaunee Scientific Fume Hood 72" X 85"
- Brinkman Tuttnauer Autoclave Steam Sterylizer Model:2540E
- Carl Zeiss Surgical Microscope
- Salvis Thermocenter. Typ: TC-40 S
- Forma-Quick Dry Glassware Dryer Stainless Steel 6097 High Performance glass Dryer
- Forma Scientific Lab Glassware Washer Model: Fury2000 Industrial Sterilizer Stainless steel
- HP Agilent HPLC System Model: 1100
Have similar assets to sell? Start selling with SVD.
We make selling at auction simpler and better.
Company Overview
-
InSite Vision is advancing new specialty ophthalmologic products for treatment of diseases affecting the front and back of the eye. The company has two commercial products based on its innovative DuraSite® platform approved for the treatment of bacterial eye infections, AzaSite® (azithromycin ophthalmic solution) 1%, marketed in the U.S. by Akorn, Inc., and Besivance® (besifloxacin ophthalmic suspension) 0.6%, marketed by Bausch & Lomb, a wholly owned subsidiary of Valeant Pharmaceuticals International. InSite Vision has a proprietary portfolio of clinical-stage product candidates, and has filed an NDA for BromSite™ (0.075% bromfenac) for the treatment of inflammation and prevention of pain associated with cataract surgery. InSite Vision currently plans to file an NDA with the FDA in 2017 for the commercial approval by the U.S. Food and Drug Administration (FDA) of DexaSite™ for the treatment of blepharitis. InSite Vision’s AzaSite Plus™ is advancing through Phase 3 clinical studies for the treatment of eye infections, and ISV-101 is in Phase 1/2 clinical development for dry-eye disease and inflammation.
State Compliance
- 1. Auctioneer/Auction Surety Bond Number 100178167
- 2. The auction is being conducted in compliance with Section 2328 of the Commercial Code, Section 535 of the Penal Code, and the provisions of the California Civil Code.